Recombinant Overlapping Peptides

Oxford Vacmedix announces major manufacturing milestone for OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, announced today that OVM-200 which was manufactured on contract by Eurofins Amatsi to exacti...
Read More

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford

New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of therapeutic cancer vaccines, announced today the award of an MRC i-Case studentship to fund a new D.Ph...
Read More

In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10

The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle.  The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read the full article: ROP-TB Diagnosis By Qing Zhang, Xiong Lu, Liang Gao, Siyu Tao, Yinghua Ge, Daocheng Cui, Renying Zhu, Wenshu Lu, Jian Wang...
Read More
en_GBEnglish